# Fred Saad

Source: https://onco.cc/people/fred-saad/  
OnCo record `fred-saad` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Montreal urologist who led the zoledronic acid trials in prostate cancer bone metastases and was lead author of ARANOTE, which established darolutamide plus hormone therapy for metastatic hormone-sensitive disease.

## Summary

Fred Saad is chief of urology at the Centre hospitalier de l'Université de Montréal and a leading investigator in advanced prostate cancer. He led the trials that established zoledronic acid for bone metastases from castration-resistant prostate cancer and was first author of the 2024 Journal of Clinical Oncology report of ARANOTE, in which darolutamide plus androgen deprivation therapy improved radiographic progression-free survival in metastatic hormone-sensitive prostate cancer.

## Fields

- Kind: Person
- Last checked: 2026-09-18
- Tags: prostate; trialist
- Role: Professor and Chief of Urology, Centre hospitalier de l'Université de Montréal
- Specialisms: Advanced prostate cancer; Bone-targeted therapy; Androgen receptor inhibitors

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Metastatic hormone-sensitive prostate cancer](https://onco.cc/cancers/prostate-mhspc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- institutions: [Centre hospitalier de l'Université de Montréal (CHUM)](https://onco.cc/institutions/chum/)
- trials: [ARANOTE](https://onco.cc/trials/aranote/)

---
JSON: https://onco.cc/api/v1/entities/fred-saad.json